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SARS-CoV-2       
Dear Editor, 
With the continued COVID-19 pandemic and the fear of a second 
wave, the world in the Northern hemisphere is facing the occurrence of 
COVID-19 and influenza with the upcoming winter season. Currently, 
there are limited therapeutic options and no available vaccine. Hetero-
typic immunity (cross-protection) is the protection of some individuals 
to subtypes of influenza virus to which they have not previously been 
exposed through natural infection or immunization. A possible expla-
nation has arisen from an understanding of the molecular targets of 
broadly neutralizing monoclonal antibodies directed against various 
portions of the hemagglutinin (HA) protein. A specific region of the HA 
stem is highly conserved among many influenza strains, and it has been 
possible to stimulate the production of stem-targeting antibodies with 
cross-neutralizing properties in several host species, including non- 
human primates. Immune responses to the 2009 H1N1 pandemic 
included broadly cross-reactive antibodies against the HA stalk and head 
domain epitopes of multiple influenza strains. In the case of the 2009 
H1N1 influenza vaccine, the majority of HA-specific antibodies from 
healthy recipients had broad cross reactivity to the HA stem, and three 
broad cross-reactive antibodies were shown to bind the HA stem. The 
identification of predictive signatures of vaccines would allow the 
development of a vaccine chip with a few hundred genes that could 
interrogate a particular type of innate or adaptive immune response (e. 
g., magnitude of effector CD8 T-cell response; frequency of Th cells; 
balance of Th1, Th2, and Th17 cells; and high-affinity antibody titers). 
Such an approach would permit rapid identification (or prediction) of 
suboptimal responses in the elderly, infants and immunocompromised 
individuals. 
Currently, there are no specific antiviral drugs or approved vaccines 
for SARS-CoV-2. Symptomatic treatment strategies are the recommen-
dation in addition to enrollment of patients in clinical therapeutic trials. 
SARS-CoV-2 infects the lower respiratory tract and cause severe pneu-
monia and may lead to fatal acute lung injury and acute respiratory 
distress syndrome (ARDS). SARS-CoV-2 may develop ways to avoid 
early detection by the immune system. Once detected by the immune 
system, this immune response may result in intense resposne such as the 
cytokine strom and may aggressively destroy infected cells and results in 
tissue and organ destruction. 
It was found that of influenza vaccination was associated with lower 
risk of COVID-19 infection and influenza vaccination rate was 93.9% 
among 5940 of non-COVID-19 vs. 6.1% among 384 COVID-19 positive 
cases [1]. In addition, 10% increase in influenza vaccination coverage 
was associated with a statistically significant 28% reduction in 
COVID-19 death rate in the elderly [2]. In a pre-print study of 92,664 
COVID-19 patients of which about one-third received influenza vaccine. 
Influenza vaccinated patients had 8% lower odds of intensive care unit 
admission, 18% lower odds of requiring mechanical ventilation and 17% 
lower odds of death [3]. It is possible that influenza vaccination could 
act as a non-specific immune stimulator in patients with COVID-19 
leading to early activation of the immune system to attack 
SARS-CoV-2 before invading cells. Stimulation of the immune system by 
influenza vaccines could occur through early activation of the immune 
system by influenza vaccine which facilitate early detection of 
SARS-CoV-2. Influenza vaccine keeps the immune system active through 
Toll-Like Receptor 7 [1]. Toll-Like Receptor 7 is an important binding of 
single-stranded RNA respiratory viruses, such as SARS-CoV-2 [4]. 
Influenza A infection up-regulates pulmonaryACE2 receptors and thus 
leads to increased SARS-CoV-2 infection [5]. 
The most common seasonal influenza vaccine given to humans is the 
inactivated trivalent vaccine, which targets the three most representa-
tive virus types in circulation (two subtypes of influenza A and one 
influenza B virus). Live attenuated influenza vaccines (LAIVs) made of 
temperature-attenuated reassortant virus also come in both trivalent 
(two subtypes of influenza A viruses and one B virus) and quadrivalent 
(with an additional B virus) form. Inactivated influenza vaccines are 
injected intramuscularly, and LAIVs are administered intranasally. For 
inactivated influenza vaccines, an HA inhibition titer of 1:40 has been 
established as an immunologic correlate of 50% protection in adults 
children require 1:110 to achieve 50% protection [6]. In a risk analysis 
study, the infection risk of SARS-CoV-2 was reduced in those who had 
pneumococcal polysaccharide or influenza vaccine [1]. In addition, live 
attenuated vaccines stimulate the innate immunity and provide tran-
sient protection against COVID-19 as SARS-CoV-2 infection was asso-
ciated with suppression of the innate immunity. Thus, it seems prudent 
than before that we continue to promote influenza vaccines in this 
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season. Further studies are needed to further deliniate the role of 
influenza vaccines in modifying the course of SARS-CoV-2 infection. 
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